If successful we will be slicing pockets of NSCLC ever more finely: KRAS G12C mutated, PD-L1 high: G12C inhibitor/checkpoint inhibitor; KRAS G12C mutated, PD-L1 zero: G12C inhibitor/chemotherapy; KRAS G12C mutated, STK11/KEAP1 mutation: G12C inhibitor/novel strategy18; and so on. Here, KRAS is linked to non-small cell lung carcinoma.